Jazz’s Midphase Tremor Drug Misses Mark, Future Uncertain by Lilu Anderson 20.06.2024 Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Aerovate Therapeutics Stock Downgraded After Trial Setback by Mark Eisenberg 17.06.2024 Aerovate Therapeutics stock downgraded by BTIG after AV-101 trial setback; mixed analyst views and future pivotal readouts crucial for investors.
Gilead’s $4.3B Bet on CymaBay’s Liver Drug by Mark Eisenberg 12.02.2024 Gilead Sciences plans to acquire CymaBay Therapeutics for $4.3 billion, expanding their liver disease portfolio. The deal is expected to ...